Dual orexin receptor antagonist (DORA) for insomnia

Dayvigo (lemborexant) Withdrawal

Dayvigo (lemborexant) is in the same orexin-antagonist class as Belsomra and shares its low dependence potential. In studies it showed minimal rebound insomnia and no significant withdrawal syndrome on stopping. Because it is newer, individual data are limited, but the class behaves very differently from benzodiazepines and Z-drugs.

By Dr. Ben Soffer, DO — board-certified physician, at-home ketamine therapy in Florida and New Jersey.

Half-life

~17-19 hours. Lemborexant is a newer hypnotic (FDA-approved 2019), so dedicated discontinuation data are limited.

Withdrawal timeline

Onset— Night 1-2 after stopping

Any return of sleep difficulty appears in the first nights.

Peak— First few nights

Mild rebound insomnia, if present, is most noticeable early and tends to be limited.

Resolution— Several nights to ~1 week

Sleep usually re-stabilizes within a week; meaningful physical withdrawal is not expected.

Common symptoms

  • Mild rebound insomnia
  • Lighter or more fragmented sleep for a few nights

Less common

  • Daytime fatigue
  • Mild anxiety about sleep

Tapering guidance

  • A strict taper is usually not required given the low dependence potential; a brief step-down after long-term nightly use can ease rebound.
  • Coordinate with the prescribing physician, especially when insomnia is part of a mood or anxiety disorder.

Where ketamine therapy fits

Ketamine therapy does not treat lemborexant discontinuation. As with other sleep agents, it can be relevant when insomnia is a downstream symptom of depression or anxiety. Coordinate with the prescribing physician to target the underlying cause.

Check ketamine therapy eligibilityMedication safety with ketamine

Frequently asked questions

Does Dayvigo cause withdrawal?

Studies show minimal rebound insomnia and no significant withdrawal syndrome. Like Belsomra, it has low dependence potential, unlike benzodiazepines or Z-drugs.

Should I taper Dayvigo?

Usually not necessary given the low dependence potential, though a brief step-down after long-term nightly use can ease any rebound.

Can ketamine therapy address the insomnia underneath?

When insomnia stems from depression or anxiety, treating the mood disorder often improves sleep. Coordinate with your prescriber to find the underlying driver.

Important: This page is informational and does not constitute medical advice or a recommendation to start, stop, or change any medication. Tapering psychiatric medications should always be coordinated with the prescribing physician. Compounded ketamine for anxiety, depression, PTSD, and chronic pain is not FDA approved.

Browse all medication withdrawal guides.